Intervention not reported
Non‐vertebral fractures · patients with multiple myeloma
The intervention showed no clear difference in non‐vertebral fractures (moderate certainty).
1 finding from 1 review
Intervention not reported
Skeletal‐related events · patients with multiple myeloma
The intervention probably leads to lower skeletal‐related events (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain · patients with multiple myeloma
It is very uncertain whether the intervention changes pain (very low certainty).
1 finding from 1 review
Intervention not reported
Osteonecrosis of jaw · patients with multiple myeloma
The intervention showed no clear difference in osteonecrosis of jaw (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (calculated instead of overall survival)
The intervention showed no clear difference in mortality (calculated instead of overall survival) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse, progression or death (calculated instead of PFS) sensitivity analysis ‐ without HD6trial due to high risk of other bias
The intervention probably leads to lower relapse, progression or death (calculated instead of PFS)… (moderate certainty).
1 finding from 1 review
HR 0.24 [0.07, 0.88]
900 participants
Moderate
Intervention not reported
Infection‐ related mortality
The intervention showed no clear difference in infection‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Second cancer‐ related mortality
The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiac disease‐ related mortality
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Complete response rate
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse, progression or death (calculated instead of PFS)
The intervention probably leads to lower relapse, progression or death (calculated instead of PFS) (moderate certainty).
1 finding from 1 review
Intervention not reported
Infection‐ related mortality
The intervention showed no clear difference in infection‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Second cancer‐ related mortality
The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiac disease‐ related mortality
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Complete response rate
The intervention showed no clear difference in complete response rate (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (calculated instead of overall survival)
The intervention may leads to higher mortality (calculated instead of overall survival) (low certainty).
1 finding from 1 review
Intervention not reported
Relapse, progression or death (calculated instead of PFS)
The intervention showed no clear difference in relapse, progression or death (calculated instead of PFS) (low certainty).
1 finding from 1 review
All‐cause mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP leads to lower mortality compared with chemotherapy including ABVD (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP probably leads to lower progression, relapse or death compared with chemotherapy including ABVD (moderate certainty).
1 finding from 1 review